AI DIR Fee Exposure Tracker
Discovery Lens
A New Behaviors
Markets that didn't exist until people started doing something new
One-Liner
Analyzes dispensing data to estimate each pharmacy's performance metric trajectory and flag prescriptions with high DIR fee exposure risk.
Kill Reason
The CMS rule change effective January 1, 2024 moved the majority of Medicare Part D DIR fees to point-of-sale, directly addressing the retrospective exposure problem this product was designed to quantify. Building a DIR fee tracker after the primary regulatory driver has been neutralized means chasing a declining problem in a heavily regulated sector where pharmacy benefit managers and enterprise pharmacy software vendors are the natural owners of any remaining analytics needs.
What do you think?
Related ideas you can explore free:
killed: Leading physical therapy platforms (WebPT, Clinicient, Raintree) already ship AI-assisted documentation and Medicare billing templates. The specific Medicare functional status distinction this tool targets will be absorbed by these incumbents as a feature update, with no room for a standalone product to establish switching costs first.
killed: Automated veterinary follow-up communication is already offered by PetDesk, VitusVet, and practice management platforms such as AVImark and Cornerstone. The diagnosis-keyed personalization layer adds marginal differentiation that incumbents will replicate as a routine feature update, leaving no defensible position for a standalone product.
killed: Dermatology allergen avoidance letters are a narrow workflow step in a tiny addressable market—fewer than 10,000 US practices perform routine patch testing. The output is a templated letter that takes five minutes to produce manually, and no dermatologist would budget for a standalone subscription product to automate a task that any AI assistant already handles for free.